A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements
Open Access
- 1 June 2023
- journal article
- review article
- Published by Springer Nature in Neurology and Therapy
- Vol. 12 (4) , 1257-1284
Abstract
Introduction Alzheimer’s disease (AD) is a disease continuum from pathophysiologic, biomarker and clinical perspectives. With the advent of advanced technologies, diagnosing and managing patients is evolving. Methods A systematic literature review (SLR) of practice guidelines for mild cognitive impairment (MCI) and AD dementia was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). This systematic literature review (SLR) aimed to summarize current clinical practice guidelines for screening, testing, diagnosis, treatment and monitoring in the AD continuum. The results of this SLR were used to propose a way forward for practice guidelines given the possible introduction of biomarker-guided technology using blood- or plasma-based assays and disease-modifying treatments (DMTs) targeted for early disease. Results 53 clinical practice guidelines were identified, 15 of which were published since 2018. Screening for asymptomatic populations was not recommended. Biomarker testing was not included in routine diagnostic practice. There was no consensus on which neurocognitive tests to use to diagnose and monitor MCI or AD dementia. Pharmacologic therapies were not recommended for MCI, while cholinesterase inhibitors and memantine were recommended for AD treatment. Discussion The pre-2018 and post-2018 practice guidelines share similar recommendations for screening, diagnosis and treatment. However, once DMTs are approved, clinicians will require guidance on the appropriate use of DMTs in a clinical setting. This guidance should include strategies for identifying eligible patients and evaluating the DMT benefit-to-risk profile to facilitate shared decision-making among physicians, patients and care partners. Conclusion Regular evidence-based updates of existing guidelines for the AD continuum are required over the coming decades to integrate rapidly evolving technologic and medical scientific advances and bring emerging approaches for management of early disease into clinical practice. This will pave the way toward biomarker-guided identification and targeted treatment and the realization of precision medicine for AD.Keywords
This publication has 33 references indexed in Scilit:
- The cholinergic system in the pathophysiology and treatment of Alzheimer’s diseaseBrain, 2018
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Practice guideline update summary: Mild cognitive impairment [RETIRED]Neurology, 2018
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteriaAlzheimer's & Dementia, 2016
- Guidelines, Clinical Practice Recommendations, Position Papers and Consensus Statements: Definition, Preparation, Role and ApplicationUltraschall in der Medizin - European Journal of Ultrasound, 2014
- Partial updating of clinical practice guidelines often makes more sense than full updating: a systematic review on methods and the development of an updating procedureJournal of Clinical Epidemiology, 2014
- Alzheimer’s Disease Dementia Guidelines for Diagnostic TestingAmerican Journal of Alzheimer's Disease and Other Dementias®, 2013
- Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline developmentImplementation Science, 2012
- Revising the definition of Alzheimer's disease: a new lexiconThe Lancet Neurology, 2010
- Practice guidelines for the clinical assessment and care management of Alzheimer's disease and other dementias among adults with intellectual disability. AAMR-IASSID Workgroup on Practice Guidelines for Care Management of Alzheimer's Disease among Adults with Intellectual Disability.1996